.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Non-valvular atrial fibrillation (NVAF) remains a significant clinical challenge for cardiologists worldwide. Research suggests that vildagliptin for atrial fibrillation may offer a novel therapeutic approach by protecting heart cells. Specifically, this dipeptidyl peptidase-4 (DPP-4) inhibitor shows potential in reducing inflammatory damage and programmed cell death. A recent 2026 study highlights the importance of specific signaling pathways in this process. Therefore, understanding these mechanisms is vital for developing better cardiovascular treatments.
Vildagliptin works by modulating the nitric oxide/soluble guanylate cyclase/cyclic guanosine monophosphate (NO/sGC/cGMP) pathway. In a recent rat model, researchers found that vildagliptin for atrial fibrillation significantly improved cardiac electrical stability. Furthermore, the drug increased levels of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP). These molecules are essential for maintaining proper heart rhythm and vascular tone. Consequently, vildagliptin helps restore the balance of signaling proteins in the heart tissue.
The study compared a drug-treated group with a control group of rats with induced atrial fibrillation. Notably, the treatment group showed a longer effective refractory period (ERP) and action potential duration (APD90). Moreover, vildagliptin significantly reduced the cardiomyocyte apoptosis index (AI) and the expression of inflammatory cytokines. Researchers also observed a downregulation of phosphodiesterase 5A (PDE5A). Ultimately, these changes suggest that vildagliptin protects the heart by preventing harmful structural remodeling.
Vildagliptin reduces inflammation and cardiomyocyte apoptosis. It achieves this by modulating the NO/sGC/cGMP signaling pathway and downregulating PDE5A, which improves cardiac electrical stability.
The primary pathway involved is the nitric oxide/soluble guanylate cyclase/cyclic guanosine monophosphate (NO/sGC/cGMP) signaling system. Vildagliptin enhances this pathway to protect heart tissue.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional physician-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Wang Z et al. Vildagliptin alleviates cardiomyocyte apoptosis and inflammatory responses in the treatment of non-valvular atrial fibrillation by regulating the NO/sGC/cGMP signaling pathway. Immunopharmacol Immunotoxicol. 2026 Apr 29. doi: 10.1080/08923973.2026.2639559. PMID: 42056726.
Liu X, et al. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. BMC Cardiovasc Disord. 2017;17(1):159.
Nicotera R, et al. Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on parameters of glucose metabolism and vascular markers. MDPI. 2024.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Vildagliptin shows potential in treating non-valvular atrial fibrillation by reducing inflammation and apoptosis via the NO/sGC/cGMP signaling pathway....
5 months ago
A retrospective cohort study of 7,716 ICU patients from the MIMIC-IV database demonstrates that Gradient Boosting Decision Trees significantly outperform traditional SOFA scores in predicting in-hospital mortality among patients with sepsis and diabetes, with SHAP analysis providing clinical interpretability.
Today
A prenatal case highlights severe glutaric acidemia type II presenting as bilateral hyperechoic cystic kidneys at 18 weeks. Whole-exome sequencing revealed a novel homozygous ETFDH frameshift variant, demonstrating the power of rapid genetic testing in fetal renal anomalies.
Today
This article reviews the forensic and clinical complexities of acute myocarditis arising on left ventricular hypertrophy in children, highlighting early diagnostic red flags and multidisciplinary postmortem autopsy protocols.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
